Estimating the cost-effectiveness of intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in England.
Cost-effectiveness analysis
glucose monitoring
intermittently scanned continuous glucose monitoring
randomised controlled trial
type one diabetes
Journal
Diabetic medicine : a journal of the British Diabetic Association
ISSN: 1464-5491
Titre abrégé: Diabet Med
Pays: England
ID NLM: 8500858
Informations de publication
Date de publication:
26 Sep 2023
26 Sep 2023
Historique:
revised:
11
09
2023
received:
23
07
2023
accepted:
18
09
2023
pubmed:
26
9
2023
medline:
26
9
2023
entrez:
26
9
2023
Statut:
aheadofprint
Résumé
We previously showed that intermittently scanned continuous glucose monitoring (isCGM) reduces HbA1c at 24 weeks compared with self-monitoring of blood glucose with finger pricking (SMBG) in adults with type 1 diabetes and high HbA1c levels (58-97 mmol/mol [7.5%-11%]). We aim to assess the economic impact of isCGM compared with SMBG. Participant-level baseline and follow-up health status (EQ-5D-5L) and within-trial healthcare resource-use data were collected. Quality-adjusted life-years (QALYs) were derived at 24 weeks, adjusting for baseline EQ-5D-5L. Participant-level costs were generated. Using the IQVIA CORE Diabetes Model, economic analysis was performed from the National Health Service perspective over a lifetime horizon, discounted at 3.5%. Within-trial EQ-5D-5L showed non-significant adjusted incremental QALY gain of 0.006 (95% CI: -0.007 to 0.019) for isCGM compared with SMBG and an adjusted cost increase of £548 (95% CI: 381-714) per participant. The lifetime projected incremental cost (95% CI) of isCGM was £1954 (-5108 to 8904) with an incremental QALY (95% CI) gain of 0.436 (0.195-0.652) resulting in an incremental cost-per-QALY of £4477. In all subgroups, isCGM had an incremental cost-per-QALY better than £20,000 compared with SMBG; for people with baseline HbA1c >75 mmol/mol (9.0%), it was cost-saving. Sensitivity analysis suggested that isCGM remains cost-effective if its effectiveness lasts for at least 7 years. While isCGM is associated with increased short-term costs, compared with SMBG, its benefits in lowering HbA1c will lead to sufficient long-term health-gains and cost-savings to justify costs, so long as the effect lasts into the medium term.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15232Subventions
Organisme : Diabetes UK
Pays : United Kingdom
Informations de copyright
© 2023 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
Références
Foster NC, Beck RW, Miller KM, et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018. Diabetes Technol Ther. 2019;21(2):66-72. doi:10.1089/dia.2018.0384
Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388(10057):2254-2263. doi:10.1016/s0140-6736(16)31535-5
Bilir SP, Hellmund R, Wehler B, Li H, Munakata J, Lamotte M. Cost-effectiveness analysis of a flash glucose monitoring system for patients with type 1 diabetes receiving intensive insulin treatment in Sweden. Eur Endocrinol. 2018;14(2):73-79. doi:10.17925/ee.2018.14.2.73
Leelarathna L, Wilmot EG. Flash forward: a review of flash glucose monitoring. Diabet Med. 2018;35(4):472-482. doi:10.1111/dme.13584
Leelarathna L, Evans ML, Neupane S, et al. Intermittently scanned continuous glucose monitoring for type 1 diabetes. N Engl J Med. 2022;387:1477-1487. doi:10.1056/NEJMoa2205650
National Institute for Health and Care Excellence. NICE guideline [NG17] -Type 1 diabetes in adults: diagnosis and management: National Institute for Health and Care Excellence (NICE). 2021.
Wilmot EG, Evans M, Barnard-Kelly K, et al. Flash glucose monitoring with the FreeStyle libre 2 compared with self-monitoring of blood glucose in suboptimally controlled type 1 diabetes: the FLASH-UK randomised controlled trial protocol. BMJ Open. 2021;11(7):e050713. doi:10.1136/bmjopen-2021-050713
Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 2018;27(1):7-22. doi:10.1002/hec.3564
NICE Decision Support Unit. Mapping EQ-5D-5L to EQ-5D-3L University of Sheffield 2022. Accessed May 1, 2022. https://nicedsu.sites.sheffield.ac.uk/methods-development/mapping-eq-5d-5l-to-3l
Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ. 2005;14(5):487-496. doi:10.1002/hec.944
Joint Formulary Committee. British National Formulary (online) London. 2021 Accessed January 11, 2022. https://bnf.nice.org.uk
Curtis LA, Burns A. Unit Costs of Health & Social Care 2020. University of Kent, Personal Social Services Research Unit; 2021.
NHS Digital. Reference Costs (Ref Costs): 2019-20 Reference Costs Collection. 2021.
Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ. 2022;376:e067975. doi:10.1136/bmj-2021-067975
McEwan P, Foos V, Palmer JL, Lamotte M, Lloyd A, Grant D. Validation of the IMS CORE diabetes model. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research. 2014;17(6):714-724. doi:10.1016/j.jval.2014.07.007
UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50(6):1140-1147. doi:10.1007/s00125-007-0599-y
Foos V, Varol N, Curtis BH, et al. Economic impact of severe and non-severe hypoglycemia in patients with type 1 and type 2 diabetes in the United States. J Med Econ. 2015;18(6):420-432. doi:10.3111/13696998.2015.1006730
Blissett R, Blissett D, Levrat-Guillen F, et al. FreeStyle libre flash glucose monitoring system for people with type 1 diabetes in the UK: a budget impact analysis. BMJ Open Diab Res Care. 2022;10(2):e002580. doi:10.1136/bmjdrc-2021-002580
Abbott Diabetes Care. IMPACT Trial data on file. 2016.
National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal 2013. Process and Methods Guides; 2013.
Matza LS, Stewart KD, Davies EW, Hellmund R, Polonsky WH, Kerr D. Health state utilities associated with glucose monitoring devices. Value Health. 2017;20(3):507-511. doi:10.1016/j.jval.2016.10.007
Deshmukh H, Wilmot EG, Gregory R, et al. Effect of flash glucose monitoring on glycemic control, hypoglycemia, diabetes-related distress, and resource utilization in the Association of British Clinical Diabetologists (ABCD) Nationwide audit. Diabetes Care. 2020;43(9):2153-2160. doi:10.2337/dc20-0738
Roze S, Isitt J, Smith-Palmer J, Javanbakht M, Lynch P. Long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring versus self-monitoring of blood glucose in patients with type 1 diabetes in the U.K. Diabetes Care. 2020;43(10):2411-2417. doi:10.2337/dc19-2213
Pease A, Zomer E, Liew D, Lo C, Earnest A, Zoungas S. Cost-effectiveness of health technologies in adults with type 1 diabetes: a systematic review and narrative synthesis. Syst Rev. 2020;9(1):171. doi:10.1186/s13643-020-01373-y
Rotondi MA, Wong O, Riddell M, Perkins B. Population-level impact and cost-effectiveness of continuous glucose monitoring and intermittently scanned continuous glucose monitoring Technologies for Adults with Type 1 diabetes in Canada: a modeling study. Diabetes Care. 2022;45(9):2012-2019. doi:10.2337/dc21-2341
Healthcare Improvement Scotland. What is the clinical and cost effectiveness of Freestyle Libre flash glucose monitoring for patients with diabetes mellitus treated with intensive insulin therapy? 2018.
National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management. Economic Modelling for Continuous Glucose Monitoring in Adults with Type 1 Diabetes; National Institute for Health and Care Excellence, London 2022.
Health Technology Wales. HEALTH TECHNOLOGY Wales (HTW) GUIDANCE 004-2 (July 2021). Freestyle Libre Flash Glucose Monitoring for the Management of Diabetes. 2021.
Kent S, Becker F, Feenstra T, et al. The challenge of transparency and validation in health economic Decision modelling: a view from Mount Hood. Pharmacoeconomics. 2019;37(11):1305-1312. doi:10.1007/s40273-019-00825-1